

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ESSEX BIO-TECHNOLOGY LIMITED**

**億勝生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1061)**

### **APPOINTMENT OF EXECUTIVE DIRECTORS AND MEMBER OF THE CORPORATE GOVERNANCE COMMITTEE**

The Board is pleased to announce that Mr. Ngiam and Ms. Yau will be appointed as executive directors of the Company with effect from 19 September 2020.

The board of directors (the “**Board**”) of Essex Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Ngiam Hian Leng Malcolm (“**Mr. Ngiam**”) and Ms. Yau Lai Man (“**Ms. Yau**”) will be appointed as executive directors of the Company with effect from 19 September 2020. Ms. Yau will also be appointed as a member of the corporate governance committee on the same date.

**Mr. Ngiam Hian Leng Malcom**, aged 36, joined the Group in 2015 and has been appointed as the deputy managing director of the Company and the president of Essex Bio-Investment Limited, a wholly-owned subsidiary of the Company, in 2018. He is also a director of Essex Bio-Pharmacy Limited, Zhuhai Essex Bio-Pharmaceutical Company Limited and Majeton Pte. Ltd., all being wholly-owned subsidiaries of the Company. Mr. Ngiam is principally responsible for strategic corporate planning, business development and overall operational management of the Group.

Prior to joining the Group, Mr. Ngiam was involved in translational and therapeutics research for more than 10 years. Mr. Ngiam leads the business development team of the Group for executing various investment projects and has direct oversight of the research and development and marketing functions of the Group. Mr. Ngiam graduated from Imperial College London and has a bachelor’s degree in Biochemistry.

In accordance with the service contract made between Mr. Ngiam and the Company, Mr. Ngiam will be appointed as an executive director of the Company with effect from 19 September 2020. The service contract between Mr. Ngiam and the Company has no fixed term but can be terminated by no less than six months' notice in writing served by either party on the other and Mr. Ngiam's appointment is subject to retirement by rotation and re-election and other related provisions as stipulated in the articles of association of the Company and the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). Mr. Ngiam is entitled to an annual salary of RMB910,000 (equivalent to approximately HK\$1,037,400), which is determined by the Board, under the recommendation from the remuneration committee of the Company, with reference to his background, qualification, experience, duties and responsibilities within the Group and the prevailing market conditions. Mr. Ngiam is also entitled to (i) a variable salary to be determined by the Board at its absolute discretion having regard to his performance and (ii) a discretionary bonus to be determined by the Board at its absolute discretion having regard to the performance of Mr. Ngiam and the overall performance of the Group.

Mr. Ngiam is the son of Mr. Ngiam Mia Je Patrick, the Chairman of the Company, and a nephew of Mr. Ngiam Mia Kiat Benjamin, a substantial shareholder of the Company. As at the date of this announcement, Mr. Ngiam was personally interested in 2,039,000 shares of the Company and also held 1,000,000 share options of the Company, which together represented 0.53% of the number of total issued shares of the Company.

**Ms. Yau Lai Man**, aged 57, joined the Group as the financial controller, company secretary and authorised representative of the Company since 2001. Ms. Yau is currently a director of Essex Bio-Pharmacy Limited, Zhuhai Essex Bio-Pharmaceutical Company Limited, Zhuhai Essex Technology Development Company Limited and UNO Medical (Zhuhai) Company Limited, all being wholly-owned subsidiaries of the Company. Ms. Yau is principally responsible for financial planning and management of the Group.

Prior to joining the Group, Ms. Yau had worked with a "big four" accounting firm and a multinational corporation. Ms. Yau is currently an independent non-executive director of Chu Kong Shipping Enterprises (Group) Company Limited, a company listed on the Main Board of the Stock Exchange (stock code: 560). Ms. Yau obtained a master degree in business administration from The University of Warwick in the United Kingdom. Ms. Yau is a member of the Hong Kong Institute of Certified Public Accountants and is also a member of the Institute of Chartered Accountants in England & Wales.

In accordance with the service contract made between Ms. Yau and the Company, Ms. Yau will be appointed as an executive director of the Company with effect from 19 September 2020. The service contract between Ms. Yau and the Company has no fixed term but can be terminated by no less than six months' notice in writing served by either party on the other and Ms. Yau's appointment is subject to retirement by rotation and re-election and other related provisions as stipulated in the articles of association of the Company and the Listing Rules. Ms. Yau is entitled to an annual salary of RMB1,533,000 (equivalent to approximately HK\$1,747,620), which is determined by the Board, under the recommendation from the remuneration committee of the Company, with reference to her background, qualification, experience, duties and responsibilities within the Group and the prevailing market conditions. Ms. Yau is also entitled to (i) a variable salary to be determined by the Board at its absolute discretion having regard to her performance and (ii) a discretionary bonus to be determined by the Board at its absolute discretion having regard to the performance of Ms. Yau and the overall performance of the Group.

Save as disclosed above, as at the date of this announcement, each of Mr. Ngiam and Ms. Yau:

- (i) has not held any other major appointments and qualifications or directorships in other listed company in the last three years;
- (ii) does not have any relationship with any directors of the Company, senior management, substantial or controlling shareholders (having the meaning ascribed to them under the Listing Rules) of the Company;
- (iii) does not hold other positions with the Group; and
- (iv) is not interested in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information to be disclosed pursuant to any of the requirement under Rule 13.51(2) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with the appointments of Mr. Ngiam and Ms. Yau.

The Board would like to take this opportunity to welcome Mr. Ngiam and Ms. Yau in joining the Board.

On behalf of the Board  
**Essex Bio-Technology Limited**  
**Ngiam Mia Je Patrick**  
*Chairman*

Hong Kong, 18 September 2020

*For the purpose of this announcement, unless otherwise indicated, conversions of RMB into HK\$ is calculated at the approximate exchange rate of RMB1.00 to HK\$1.14. This exchange rate is adopted for the purpose of illustration purpose only and does not constitute a representation that any amounts have been, could have been, or may be, exchanged at this rate or any other rates at all.*

*Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick and Mr. Fang Haizhou. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.*